Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Ramifications of changes we are seeing. The methodology of RG is nice to see.

Ramifications of changes we are seeing. The methodology of RG is nice to see.

posted on Jan 06, 2009 10:11AM

While I believe Cohen report greatly underestimates the MMP potential, I can appreciate what is transforming. This stock is becoming something that will attract patient shareholders holding on for the year after year growth. The confidence beginning to swell from RG is obvious. We are used to constant disappointment and now we see more conservative forecasts coupled with actually meeting or exceeding said expectations. We will see less "flippers", day traders, hypsters and doomsayers. This stability is welcome.

More welcome will be another year of continued growth, something positive pertaining to our patents resulting in dozens of signings in one month, and our application for Nasdaq. Chug along RG, the little train that could.

And with that, I think Cohen underestimates our potential ten fold. But that is ok, better to have a pleasant surprise than the constant disappointments we are used to having.

Stability, growth, no debt, solid leader, great chat room support, what more could you look for in a company? ok ok, a Nasdaq company without a R/S.

Share
New Message
Please login to post a reply